- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03261011
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors
March 8, 2018 updated by: Akesobio Australia Pty Ltd
A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK104 as a single agent in adult subjects with advanced solid tumor malignancies.
The study consists of a dose escalation phase (Phase 1a) to determine the maximum tolerated dose (MTD), or recommended Phase 2 dose (RP2D) for AK104 as a single agent, and a dose expansion phase (Phase 1b) which will characterize treatment of AK104 as a single agent at the MTD or RP2D.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
153
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xiaoping Jin, PhD
- Phone Number: +86 (0760) 8987 3999
- Email: clinicaltrials@akesobio.com
Study Locations
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Recruiting
- Monash Health
-
Contact:
- Phone Number: +61 (0) 3 8572 2429
-
Principal Investigator:
- Benjamin Markman, MBBS
-
Heidelberg, Victoria, Australia, 3084
- Recruiting
- Austin Health
-
Contact:
- Phone Number: +61 (03) 9496 5354
-
Principal Investigator:
- Hui Gan, MBBS
-
Melbourne, Victoria, Australia, 3002
- Recruiting
- Peter Maccallum Cancer Centre
-
Contact:
- Phone Number: +61 (03) 8559 5000
-
Principal Investigator:
- Ben Tran, MBBS
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Recruiting
- Linear Clinical Research/Sir Charles Gairdner Hospital
-
Contact:
- Phone Number: +61 (0) 8 6382 5100
-
Principal Investigator:
- Michael Millward, MBBS
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Written and signed informed consent and any locally required authorization obtained from the subject/legal representative.
- In dose-escalation cohorts (Phase 1a), histologically or cytologically documented advanced or metastatic solid tumor that is refractory/relapsed to standard therapies, or for which no effective standard therapy is available, or the subject refuses standard therapy.
- In the dose-expansion cohorts (Phase 1b), histologically or cytologically confirmed selected advanced solid tumors (to be determined). Subjects must have received no more than three prior lines of systemic therapy for advanced or metastatic disease.
- Subject must have at least one measurable lesion according to RECIST Version1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.
- Available archived tumor tissue sample to allow for correlative biomarker studies. In the setting where archival material is unavailable or unsuitable for use, the subject must consent and undergo fresh tumor biopsy.
- Adequate organ function.
Exclusion Criteria:
- History of severe hypersensitivity reactions to other mAbs.
- Prior exposure to any anti-PD-1, anti-PD-L1, anti-CTL4 antibody or any other antibody or drug targeting T-cell costimulation or checkpoint pathways such as ICOS, or agonists such as CD40, CD137, GITR, OX40 etc.
- Receipt of any immunotherapy, any conventional or investigational systemic anticancer therapy within 4 weeks prior to the first dose of AK104; in the case of mAbs, 6 weeks prior to the first dose of AK104.
- Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment. Concurrent use of hormones for non-cancer-related conditions is acceptable.
- Subjects with a condition requiring systemic treatment with either corticosteroid (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration.
- Active or prior documented autoimmune disease within the past 2 years.
- Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).
- History of primary immunodeficiency.
- History of organ transplant or hematopoietic stem cell that requires use of immunosuppressives.
- Known allergy or reaction to any component of the AK104 formulation.
- History of interstitial lung disease or non-infectious pneumonitis except for those induced by radiation therapies.
- Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.
- Known history of tuberculosis.
- Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
- Any positive test for hepatitis B or hepatitis C virus indicating acute or chronic infection except for subjects with HCC.
- An active infection requiring systemic therapy with the exception of anti-viral therapy for hepatitis as specified by the protocol.
- Receipt of live or attenuated vaccination within 30 days prior to the first dose of AK104.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AK-104
Single-arm
|
Subjects will receive AK104 by intravenous administration.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with adverse events (AEs)
Time Frame: From the time of informed consent signed through 90 days after the last dose of AK104, up to 2 years and 3 months
|
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.
|
From the time of informed consent signed through 90 days after the last dose of AK104, up to 2 years and 3 months
|
Number of participants with a Dose Limiting Toxicity (DLT)
Time Frame: During the first 4 weeks
|
DLTs will be assessed during the first 4 weeks of treatment for dose-escalation phase and are defined as toxicities that meet pre-defined severity criteria, and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle (4 weeks) of treatment.
|
During the first 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: Up to 3 years
|
The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1.
|
Up to 3 years
|
Disease control rate (DCR)
Time Frame: Up to 3 years
|
The DCR is defined as the proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for ≥8 weeks) based on RECIST Version 1.1.
|
Up to 3 years
|
Duration of response (DoR)
Time Frame: Up to 3 years
|
Duration of response is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.
|
Up to 3 years
|
Progression-free survival (PFS)
Time Frame: Up to 3 years
|
Progression-free survival is defined as the time from the start of treatment with AK104 until the first documentation of disease progression or death due to any cause, whichever occurs first.
|
Up to 3 years
|
Overall survival (OS)
Time Frame: Up to 3 years
|
Overall survival is defined as the time from the start of treatment with AK104 until death due to any cause.
|
Up to 3 years
|
Area under the curve (AUC) of AK104
Time Frame: From first dose of AK104 through 90 days after last dose of AK104; Up to 2 years and 3 months.
|
The endpoints for assessment of PK of AK104 include serum concentrations of AK104 at different timepoints after AK104 administration.
|
From first dose of AK104 through 90 days after last dose of AK104; Up to 2 years and 3 months.
|
Maximum observed concentration (Cmax) of AK104
Time Frame: From first dose of AK104 through to 90 days after last dose of AK104; Up to 2 years and 3 months.
|
The endpoints for assessment of PK of AK104 include serum concentrations of AK104 at different timepoints after AK104 administration.
|
From first dose of AK104 through to 90 days after last dose of AK104; Up to 2 years and 3 months.
|
Minimum observed concentration (Cmin) of AK104 at steady state
Time Frame: From first dose of AK104 through to 90 days after last dose of AK104; Up to 2 years and 3 months.
|
The endpoints for assessment of PK of AK104 include serum concentrations of AK104 at different timepoints after AK104 administration.
|
From first dose of AK104 through to 90 days after last dose of AK104; Up to 2 years and 3 months.
|
Number of subjects who develop detectable anti-drug antibodies (ADAs)
Time Frame: From first dose of AK104 through to 90 days after last dose of AK104; Up to 2 years and 3 months.
|
The immunogenicity of AK104 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs).
|
From first dose of AK104 through to 90 days after last dose of AK104; Up to 2 years and 3 months.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 3, 2017
Primary Completion (Anticipated)
March 1, 2020
Study Completion (Anticipated)
September 1, 2020
Study Registration Dates
First Submitted
August 20, 2017
First Submitted That Met QC Criteria
August 22, 2017
First Posted (Actual)
August 24, 2017
Study Record Updates
Last Update Posted (Actual)
March 9, 2018
Last Update Submitted That Met QC Criteria
March 8, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Other Study ID Numbers
- AK104-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Cancer
-
STORM Therapeutics LTDRecruitingCancer | Advanced Solid Tumor | Advanced CancerUnited States
-
Merck Sharp & Dohme LLCCompletedAdvanced Cancer Relapsed | Advanced Cancer Refractory
-
BiOneCure Therapeutics Inc.RecruitingCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Teon Therapeutics, Inc.Merck Sharp & Dohme LLCTerminatedCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Zhejiang UniversityRecruitingAdvanced Colorectal Cancer | Advanced Hepatocellular Carcinoma | Advanced Gastric Cancer | Advanced Pancreatic CancerChina
-
PfizerTerminatedAdvanced Solid Tumors | Advanced CancerUnited States
-
AVEO Pharmaceuticals, Inc.CompletedAdvanced Cancer | Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
University Health Network, TorontoUniversity of UlmRecruiting
-
Bristol-Myers SquibbActive, not recruitingAdvanced CancerFrance, United States, Spain, Canada, Argentina, Chile, Italy
Clinical Trials on AK-104
-
National Taiwan University HospitalUnknownEnd-Stage Renal DiseaseTaiwan
-
Milton S. Hershey Medical CenterEnrolling by invitationCataract | AstigmatismUnited States
-
Dolorgiet GmbH & Co. KGd.s.h. statistical services GmbH; CenTrial GmbHCompletedActinic Keratosis Olsen Grade I/IIGermany
-
InQpharm GroupCompletedAppetite Regulation | Energy Intake | Appetite SuppressionGermany
-
Stanford UniversityNot yet recruitingHead and Neck Disorder | Warthin Tumor | Pleomorphic Adenoma of the ParotidUnited States
-
PeplinCompleted
-
PeplinCompletedActinic KeratosisUnited States, Australia
-
PeplinTKL Research, Inc.CompletedActinic KeratosisUnited States, Australia
-
Eli Lilly and CompanyAurKa Pharma Inc.CompletedNeoplasms | Breast Neoplasms | Head and Neck Neoplasms | Small Cell Lung Carcinoma | Neoplasm Metastasis | Triple Negative Breast Neoplasms | Solid Tumor, AdultCanada
-
InQpharm GroupCompleted